Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Astrazeneca Plc (AZN)

49.2   0.05 (0.1%) 02-25 12:25
Open: 49.845 Pre. Close: 49.15
High: 49.87 Low: 49.065
Volume: 8,319,321 Market Cap: 129,579M
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); and Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 50.344 - 50.648 50.648 - 50.939
Low: 48.789 - 49.148 49.148 - 49.492
Close: 49.549 - 50.078 50.078 - 50.586

Technical analysis

as of: 2021-02-25 11:42:23 AM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 61.41     One year: 63.83
Support: Support1: 49.22    Support2: 40.95
Resistance: Resistance1: 52.58    Resistance2: 54.65
Pivot: 50.40
Moving Average: MA(5): 49.99     MA(20): 50.46
MA(100): 52.23     MA(250): 52.15
MACD: MACD(12,26): -0.36     Signal(9): -0.25
Stochastic oscillator: %K(14,3): 13.35     %D(3): 21.99
RSI: RSI(14): 41.44
52-week: High: 64.94  Low: 36.15  Change(%): 12.7
Average Vol(K): 3-Month: 1227596  10-Days: 1045391

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
AZN has closed above bottom band by 12.9%. Bollinger Bands are 43.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to AZN's normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Wed, 24 Feb 2021
AZN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies AstraZeneca PLC Shareholders of Class Action and Encourages Shareholders to Contact the Firm - Yahoo Finance

Wed, 24 Feb 2021
Astrazeneca PLC (AZN) Ex-Dividend Date Scheduled for February 25, 2021 - Nasdaq

Wed, 24 Feb 2021
AstraZeneca Hopes New Data Gets Its Covid Vaccine Back on Track - Bloomberg

Tue, 23 Feb 2021
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline – AZN - Yahoo Finance

Thu, 18 Feb 2021
Is AstraZeneca (AZN) Stock a Buy For 2021? - Yahoo Finance

Sat, 13 Feb 2021
AZN LOSS NOTICE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages AstraZeneca PLC Investors with Large Losses to Secure QUALIFIED COUNSEL Before Important Deadline – AZN - Yahoo Finance

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Neutral Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers General
Shares Out. (M) 2,630
Shares Float (M) 2,620
% Held by Insiders
% Held by Institutions 16.82
Shares Short (K) 49,930
Shares Short P. Month (K) 3,460

Stock Financials

EPS 0.950
EPS Est This Year 1.910
EPS Est Next Year 1.700
Book Value (p.s.) 4.650
Profit Margin 9.65
Operating Margin 19.86
Return on Assets (ttm) 5.2
Return on Equity (ttm) 17.7
Qtrly Rev. Growth 2.7
Gross Profit (p.s.) 7.430
Sales Per Share 9.837
EBITDA (p.s.) 2.928
Qtrly Earnings Growth 116.70
Operating Cash Flow (M) 4,380
Levered Free Cash Flow (M) 4,980

Stock Valuations

PE Ratio 51.95
PEG Ratio
Price to Book value 10.61
Price to Sales 5.02
Price to Cash Flow 29.64

Stock Dividends

Dividend 2.800
Forward Dividend 1.400
Dividend Yield 0.06
Dividend Pay Date 2020-09-13
Ex-Dividend Date 2020-08-12
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.